A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S‐1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Issue 18 (24th June 2013)

• Record Type: Journal Article
• Authors: Yamaguchi, Hironori; Kitayama, Joji; Ishigami, Hironori; Emoto, Shigenobu; Yamashita, Hiroharu; Watanabe, Toshiaki
• Is Part Of: Cancer. Volume 119:Issue 18(2013)
• Page Start: 3354
• Page End: 3358
• Publication Date: 2013-06-24
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.28204
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cncr28204-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>The prognosis of patients with gastric cancer with peritoneal metastasis is extremely poor. This phase 2 study evaluated the benefits and tolerability of weekly intravenous and intraperitoneal paclitaxel (PTX) treatment combined with oral S‐1 in patients with gastric cancer who had macroscopic peritoneal metastasis.</p> </sec> <sec id="cncr28204-sec-0002" sec-type="section"> <title>METHODS</title> <p>Patients with gastric cancer who had primary tumors with macroscopic peritoneal metastasis were enrolled. PTX was administered intravenously at 50 mg/m<sup>2</sup> and intraperitoneally at 20 mg/m<sup>2</sup> on days 1 and 8, respectively. S‐1 was administered at 80 mg/m<sup>2</sup> per day for 14 consecutive days, followed by 7 days of rest. The primary endpoint was the 1‐year overall survival (OS) rate. The secondary endpoints were the response rate, efficacy against malignant ascites, and safety.</p> </sec> <sec id="cncr28204-sec-0003" sec-type="section"> <title>RESULTS</title> <p>Thirty‐five patients were enrolled. The median number of treatment courses was 11 (range, 2‐35). The 1‐year OS rate was 77.1% (95% confidence interval, 60.5‐88.1). The overall response rate was 71% in 7 patients with target lesions. Malignant ascites disappeared or decreased in 15 of 22 (68%) patients. The frequent grade 3/4 toxic effects were neutropenia (34%), leukopenia (23%), and anemia (9%).</p> </sec> <sec id="cncr28204-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>Combination chemotherapy consisting of intravenous and intraperitoneal PTX with S‐1 is well‐tolerated and effective in patients with gastric cancer who have macroscopic peritoneal metastasis. <bold><italic>Cancer</italic> 2013;119:3354–8</bold>. © <italic>2013 American Cancer Society</italic>.</p> </sec> </abstract>